Business and Finance

Internationalization of drug wholesaling is a factor in the name change

Branded products are 92% US market in dollar value, says IMS Institute

Bloomberg BusinessWeek rakes over charitable copay programs

PhRMA-sponsored study outlines the economic effects of US-based operations

Deals with Amgen and Sanofi/Regeneron enhance new pricing policies for specialty drugs

Managed care organizations are adjusting rapidly to onslaught of specialty products

The SP channel continues to grow, with manufacturers looking for more control over access

Both clinical research and commercial analytics markets to be served by combination

More healthcare stakeholders line up against the industry

Better access to hospital systems is a goal; pharmaceutical business is fading

Double-digit growth (12.2%) for the second year running

US tax rules scuttle merger, while the US' second biosimilar wins FDA approval

Experience--mostly in Europe--indicates a heavy educational burden for patients and physicians

Partnership combines mail-order PBM with brick-and-mortar drugstores

Annual report highlights company's cost-control measures

New subsidiary of The Medical Affairs Co. hopes to fill gaps in CSO offerings

Discerning how and where products are discounted is an expensive headache for manufacturers

A new, market-driven model of drug development and commercialization is appearing*

Looking at 'cost' and 'value' under different evaluation processes

Quad-C investment will enable future acquisitions

Canada's Rexall chain, plus Biologics, Inc, and Vantage Oncology

New healthcare proposals re-open talk of drug importation

Global drug-wholesaler group plans future educational and developmental work